Gene Assay May Guide Chemo Use in Early NSCLC: ASCO 2025

Early Data Suggest that a 14-Gene Molecular Assay May Help Predict Recurrence Risk in Patients with Early-Stage Non-Squamous NSCLC - ILCN.org (ILCN/WCLC)

A 14-gene molecular assay may offer clinicians a new, data-driven approach to making post-surgical treatment decisions for patients with early-stage non-squamous non-small cell lung cancer (NSCLC). This molecular treatment stratification test successfully identified a high-risk population of patients with stage IA-IIA non-squamous NSCLC who may benefit from chemotherapy after surgery, according to recent results from an international clinical tr…

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.

Chemo With Molecular Guidance Improves Survival in Early NSCLC

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.

Gene Assay May Guide Chemo Use in Early NSCLC: ASCO 2025

A 14-gene molecular assay may help identify early-stage non-squamous NSCLC patients who benefit from chemotherapy post-surgery, potentially guiding adjuvant treatment decisions.

Molecularly Guided Chemotherapy Boosts Survival in Early NSCLC

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.